153 related articles for article (PubMed ID: 26439308)
1. Paritaprevir/ritonavir, ombitasvir, and dasabuvir for treatment of recurrent hepatitis C virus infection in the human immunodeficiency virus coinfected liver transplant recipient.
Sollima S; Milazzo L; Torre A; Calvi E; Regalia E; Antinori S
Liver Transpl; 2016 Feb; 22(2):252-3. PubMed ID: 26439308
[No Abstract] [Full Text] [Related]
2. Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.
Cheng EY; Saab S; Holt CD; Busuttil RW
Expert Opin Pharmacother; 2015; 16(18):2835-48. PubMed ID: 26646975
[TBL] [Abstract][Full Text] [Related]
3. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
Klibanov OM; Gale SE; Santevecchi B
Ann Pharmacother; 2015 May; 49(5):566-81. PubMed ID: 25680759
[TBL] [Abstract][Full Text] [Related]
4. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
Tronina O; Durlik M; Wawrzynowicz-Syczewska M; Buivydiene A; Katzarov K; Kupcinskas L; Tolmane I; Karpińska E; Pisula A; Karwowska KM; Bolewska B; Jabłkowski M; Rostkowska K; Jakutiene J; Simonova M; Flisiak R
Ann Transplant; 2017 Apr; 22():199-207. PubMed ID: 28386057
[TBL] [Abstract][Full Text] [Related]
5. Successful retreatment of a patient with chronic hepatitis C genotype 2k/1b virus with ombitasvir/paritaprevir/ritonavir plus dasabuvir.
Todt D; Schlevogt B; Deterding K; Grundhoff A; Manns MP; Wedemeyer H; Fischer N; Cornberg M; Steinmann E
J Antimicrob Chemother; 2017 May; 72(5):1541-1543. PubMed ID: 28100444
[No Abstract] [Full Text] [Related]
6. Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma.
Krastev Z; Jelev D; Antonov K; Petkova T; Atanasova E; Zheleva N; Tomov B; Boyanova Y; Mateva L
World J Gastroenterol; 2016 Feb; 22(8):2630-5. PubMed ID: 26937151
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV.
Saab S; Gonzalez YS; Huber C; Wang A; Juday T
Liver Int; 2016 Apr; 36(4):515-21. PubMed ID: 26610059
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis.
Wu J; Huang P; Fan H; Tian T; Xia X; Fu Z; Wang Y; Ye X; Yue M; Zhang Y
Virol J; 2019 Jan; 16(1):11. PubMed ID: 30654809
[TBL] [Abstract][Full Text] [Related]
9. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
Andreone P; Colombo MG; Enejosa JV; Koksal I; Ferenci P; Maieron A; Müllhaupt B; Horsmans Y; Weiland O; Reesink HW; Rodrigues L; Hu YB; Podsadecki T; Bernstein B
Gastroenterology; 2014 Aug; 147(2):359-365.e1. PubMed ID: 24818763
[TBL] [Abstract][Full Text] [Related]
10. Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient.
Cattaneo D; Sollima S; Charbe N; Resnati C; Clementi E; Gervasoni C
Eur J Clin Pharmacol; 2016 Mar; 72(3):365-7. PubMed ID: 26362279
[No Abstract] [Full Text] [Related]
11. Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses.
King JR; Khatri A; Trinh R; Viani RM; Ding B; Zha J; Menon R
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27919899
[TBL] [Abstract][Full Text] [Related]
12. Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice.
Pineda JA; Rivero-Juárez A; de Los Santos I; Collado A; Merino D; Morano-Amado LE; Ríos MJ; Pérez-Pérez M; Téllez F; Palacios R; Pérez AB; Mancebo M; Rivero A; Macías J
HIV Clin Trials; 2018 Feb; 19(1):23-30. PubMed ID: 29447085
[TBL] [Abstract][Full Text] [Related]
13. Ledipasvir/sofosbuvir; ombitasvir/paritaprevir/ritonavir/dasabuvir sodium monohydrate; and peramivir.
Hussar DA; Kavelak HL
J Am Pharm Assoc (2003); 2015; 55(2):216, 219-20, 222. PubMed ID: 25749267
[No Abstract] [Full Text] [Related]
14. Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients.
Özer Etik D; Suna N; Öcal S; Selçuk H; Dağlı Ü; Çolak T; Hilmioğlu F; Boyacıoğlu AS; Haberal M
Exp Clin Transplant; 2019 Feb; 17(1):52-58. PubMed ID: 30719954
[TBL] [Abstract][Full Text] [Related]
15. Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
Isakov V; Paduta D; Viani RM; Enejosa JV; Pasechnikov V; Znoyko O; Ogurtsov P; Bogomolov PO; Maevskaya MV; Chen X; Shulman NS
Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1073-1076. PubMed ID: 29762255
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
Khatri A; Dutta S; Wang H; Podsadecki T; Trinh R; Awni W; Menon R
Clin Infect Dis; 2016 Apr; 62(8):972-9. PubMed ID: 26740513
[TBL] [Abstract][Full Text] [Related]
17. Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.
Khatri A; Mensing S; Podsadecki T; Awni W; Menon R; Dutta S
Clin Drug Investig; 2016 Aug; 36(8):625-35. PubMed ID: 27153823
[TBL] [Abstract][Full Text] [Related]
18. An interferon-free antiviral regimen for HCV after liver transplantation.
Kwo PY; Mantry PS; Coakley E; Te HS; Vargas HE; Brown R; Gordon F; Levitsky J; Terrault NA; Burton JR; Xie W; Setze C; Badri P; Pilot-Matias T; Vilchez RA; Forns X
N Engl J Med; 2014 Dec; 371(25):2375-82. PubMed ID: 25386767
[TBL] [Abstract][Full Text] [Related]
19. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
Petta S; Marzioni M; Russo P; Aghemo A; Alberti A; Ascione A; Antinori A; Bruno R; Bruno S; Chirianni A; Gaeta GB; Giannini EG; Merli M; Messina V; Montilla S; Perno CF; Puoti M; Raimondo G; Rendina M; Silberstein FC; Villa E; Zignego AL; Pani L; Craxì A; ;
Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):427-434. PubMed ID: 28497758
[TBL] [Abstract][Full Text] [Related]
20. Working together to tackle HCV infection: ombitasvir/paritaprevir/ritonavir and dasabuvir combination.
Gamal N; Andreone P
Drugs Today (Barc); 2015 May; 51(5):303-14. PubMed ID: 26097903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]